In the new publication from GIRFT (Get It Right First Time) “to ensure that serial referrals are avoided and that all relevant treatment options are considered, each tertiary centre should have a single point of entry into a pathway for the assessment of patients referred for consideration of intervention for severe aortic valve disease and another for the assessment of severe mitral/tricuspid disease. Referrals should be made to the relevant heart team rather than to an individual cardiologist or surgeon¹.”
Check our latest articles
- 1Clarke, S and Ray, S (2021) GIRFT Programme National Specialty Report, Cardiology pg 38. Available at: https://www.gettingitrightfirsttime.co.uk/wp-content/uploads/2021/02/Cardiology-10-03i-EMBARGOED.pdf
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.
Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER 3, SAPIEN, and SAPIEN 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
©2022 Edwards Lifesciences Corporation. All rights reserved. PP–EU-3409 v1.0